文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

大流行疾病疫苗接种后特殊关注不良事件的主动监测方法:范围综述

Active surveillance methods to identify adverse events of special interest (AESIs) following vaccination against pandemic diseases: A scoping review.
PubMed 文献 · Vaccine · 2026-02-20

该范围综述汇总了427项关于流感与COVID-19疫苗主动监测特殊关注不良事件(AESI)的研究方法学证据。多数研究发表于2020年后(74.0%)并聚焦COVID-19疫苗(69.3%),以回顾性队列设计(40.5%)为主,使用登记数据库(24.0%)和电子健康记录(22.4%)。神经与心脏AESI最常被调查,主动监测集中于高收入国家,方法学差异大。

要点

  • 主动监测研究多聚焦COVID-19疫苗(69.3%)与mRNA平台(51.3%),以回顾性队列设计为主。
  • 神经与心脏AESI最常被调查,尤其吉兰-巴雷综合征与心肌炎。
  • 主动监测集中于高收入国家(85.5%),中低收入国家方法学引入亟需加强。

核心结论

  • 疫苗安全主动监测研究增多但集中于高收入国家。
  • 检测、核实与验证的方法学差异广泛。
  • 中低收入国家引入主动监测方法学对全球公平监测至关重要。

研究设计与样本

  • 范围综述,遵循PRISMA-ScR指南,检索PubMed、Embase、Web of Science、Scopus、Google Scholar及手动检索。
  • 纳入427项研究,由两名作者独立筛选并提取研究特征、方法与结局数据。
  • 采用叙述性综合并以表格和图形呈现结果。

主要发现

  • 427项研究中74.0%发表于2020年后,69.3%聚焦COVID-19疫苗,51.3%涉及mRNA平台。
  • 85.5%来自高收入国家,跨国研究占6.6%,单中心但覆盖国家或次国家范围的研究占63.0%。
  • 队列设计占40.5%(其中回顾性74.2%),使用登记数据库24.0%、电子健康记录22.4%,人工智能用于信号检测与预测占2.7%。
  • 49.6%链接多个数据源,但报告结局核实的研究不足半数(45.9%)。
  • 最常报告发病率为16.5%、风险/风险比为14.8%;神经AESI占21.8%、心脏AESI占21.3%,尤其吉兰-巴雷综合征与心肌炎。

临床怎么用

  • 主动监测设计可参考以队列为主、链接多数据源并纳入结局核实的模式。
  • 信号检测可结合登记数据库与电子健康记录,人工智能应用尚少。
  • 资源有限地区可优先引入主动监测方法学以弥补被动监测不足。

局限性

  • 纳入研究方法学差异广泛,难以直接比较或合并。
  • 研究集中于高收入国家,中低收入国家证据代表性不足。
  • 结局核实报告率不足半数,可能影响AESI确认的完整性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Active post-vaccination surveillance is vital for ensuring vaccine safety, particularly in monitoring Adverse Events of Special Interest (AESIs). This scoping review synthesises evidence on methodologies employed in active surveillance studies, with a focus on influenza and COVID-19 vaccines. METHODS: Literature was identified via PubMed, Embase, Web of Science, Scopus, Google Scholar, and manual searches, using key terms including influenza, COVID-19, vaccine, and AESI. Two authors independently screened studies and extracted data on study characteristics, methods, and outcomes. Findings were synthesised narratively and presented in tables and figures, following the PRISMA-ScR guideline. RESULTS: Of 427 included studies, most were published after 2020 (74.0%) and focused on COVID-19 vaccines (69.3%), particularly mRNA platforms (51.3%). The majority were conducted in North America and Europe, with 85.5% from high-income countries; multinational studies accounted for 6.6%, and single-centre studies with national or subnational coverage for 63.0%. Cohort designs predominated (40.5%), mostly retrospective (74.2%), utilising registries (24.0%) and electronic health records (22.4%), including artificial intelligence for signal detection and prediction (2.7%). Nearly half (49.6%) linked multiple data sources, though outcome verification was reported in fewer than half (45.9%). Incidence rates (16.5%) and risk/hazard ratios (14.8%) were the most reported measures. Neurological (21.8%) and cardiac (21.3%) AESIs, particularly Guillain-Barré Syndrome and myocarditis, were most frequently investigated. CONCLUSION: Active surveillance for vaccine safety has increased but remains concentrated in high-income countries. Methodological approaches to detection, verification, and validation vary widely. Introducing active surveillance methodologies in low- and middle-income countries is crucial to achieving more equitable global monitoring of vaccine safety.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chandra LA, Nugroho DB, Thobari JA, et al. Active surveillance methods to identify adverse events of special interest (AESIs) following vaccination against pandemic diseases: A scoping review. Vaccine. 2026. PMID: 41719864. doi:10.1016/j.vaccine.2026.128341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。